Details

Autor(en) / Beteiligte

• Nishiguchi, S
• Kuroki, T
• Nakatani, S
• Morimoto, H
• Takeda, T
• Nakajima, S
• Shiomi, S
• Seki, S
• Kobayashi, K
• Otani, S

Titel

Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis

Ist Teil von

• The Lancet (British edition), 1995-10, Vol.346 (8982), p.1051-1055

Ort / Verlag

London: Elsevier Ltd

Erscheinungsjahr

1995

Link zum Volltext

Quelle

EBSCOhost Business Source Ultimate

Beschreibungen/Notizen

• Summary Patients with chronic active hepatitis C and cirrhosis often develop hepatocellular carcinoma. Interferon (IFN) seems to be effective in some patients but whether it prevents carcinogenesis is unknown. In a prospective randomised controlled trial, we evaluated the effects of IFN-α in cirrhotic patients with HCV infection because of their high risk of hepatocellular carcinoma. 90 patients with compensated chronic active hepatitis C with cirrhosis were randomly allocated to receive IFN-α (6 MU three times weekly for 12-24 weeks) (45 patients) or symptomatic treatment (45 controls), and were followed up for 2-7 years. In nine controls, alanine aminotransferase (ALT) decreased to less than 80 IU/L but did not stay in the normal range. In 19 patients given IFN-α, ALT decreased to less than 80 IU/L (in seven patients, it became and stayed normal; p=0·011, Wilcoxon rank-sum test). However, the mean change in ALT was not significantly different between the two groups. The mean change in peak α-fetoprotein values was smaller in patients given IFN-α than in controls (p=0·021). The mean change in the serum albumin level was higher in the IFN-α group (p<0·001) The histological activity index in the 12 IFN-α patients undergoing a second biopsy after therapy was improved (p=0·031). Hepatitis C viral RNA disappeared in seven (16%) of the 45 IFN-α patients (95% Cl, 7-29%) and in none of the 45 controls (0-8%; p=0·018). Hepatocellular carcinoma was detected in two (4%, 1-15%) IFN-α patients and 17 (38%, 24-54%) controls (p=0·002, Wilcoxon signed-rank test). The risk ratio of IFN-α treatment versus symptomatic treatment was 0·067 (0·009-0·530; p=0·010 Cox's proportional hazards). IFN-α improved liver function in chronic active hepatitis C with cirrhosis, and its use was associated with a decreased incidence of hepatocellular carcinoma.